⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146291 | 0.79 | GRIA1 (0.40) | — | |
| SCHEMBL24074759 | 0.78 | — | — | |
| SCHEMBL21620909 | 0.78 | — | — | |
| SCHEMBL24075098 | 0.78 | — | — | |
| SCHEMBL18210893 | 0.78 | — | — | |
| SCHEMBL15618590 | 0.76 | ANPEP (0.39) | — | |
| SCHEMBL20440093 | 0.74 | — | — | |
| SCHEMBL8277105 | 0.74 | GRIA1 (0.37) | — | |
| SCHEMBL14985584 | 0.74 | — | — | |
| SCHEMBL605796 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | claimed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | claimed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | claimed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | claimed |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| CN-1071756-C | Pyrazol-4-ylbenzoyl derivatives and their use as herbicides | BASF AG (DE) | 2001-09-26 | — | — | CN | disclosed |
| EP-0384677-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0384676-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1993-11-10 | — | — | EP | disclosed |
| US-4981848-A | CARDIOVASCULAR, HYPOTENSIVE, ANTIDEPRESSANT | SMITHKLINE BEECHAM CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| US-4981849-A | OBESITY, DIABETES, CARDIOVASCULAR DISORDERS, DEPRESSION | SMITHKLINE BEECHAM CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0384677-A1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-29 | — | — | EP | disclosed |
| EP-0384676-A1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-29 | — | — | EP | disclosed |